In vitro, both liver injury-related (AST and ALT) and cholestasis-related (γ-GT, ALP, TBIL, DBIL, and TBA) biomarkers were increased in the primary hepatocytes treated with TCDC. The gene discussed is GPT; the disease is cholestasis.